Ceapro Inc. Announces Positive Data from Bioavailability Studies Evaluating CoQ10 Formulations Impregnated with PGX-Processed Carriers
October 13, 2022 08:35 ET
|
Ceapro Inc.
Findings from this collaborative project with the University of Alberta using a unique surgical methodology illustrate how PGX-processed carriers can successfully be uniformly loaded with a...
Ceapro Inc. Reports Record 2022 Second Quarter and Six-Month Financial Results and Provides Corporate Update
August 24, 2022 09:00 ET
|
Ceapro Inc.
– Company boasts highest second quarter sales to date; Q2 2022 sales of $5,500,000 vs $4,409,000 in Q2 2021, a 25% increase – YTD Sales increased 28% vs 2021 – $11,672,000 vs $9,110,000 – Income...
Ceapro Inc. Expands Collaborative Research Program with McMaster University to Develop an Inhalable Immuno-Therapeutic/-Prophylactic for COVID-19-Induced Lung Fibrosis
August 11, 2022 09:05 ET
|
Ceapro Inc.
– Continuation of research with McMaster University to validate the anti-fibrotic properties of the Company’s PGX-Processed yeast beta glucan in experimental models of lung fibrosis and to pave the...
Ceapro Inc. Announces Publication of Positive Results for PGX-Processed Alginates Impregnated with CoQ10 in The Journal of Supercritical Fluids
August 09, 2022 09:00 ET
|
Ceapro Inc.
– PGX Technology continues to demonstrate the ability to generate superior novel bioactive delivery systems – Findings from the collaborative project with the University of Alberta illustrate how...
Ceapro Bolsters Executive Management Team with Appointment of Sigrun Watson as Chief Revenue Officer
July 12, 2022 08:35 ET
|
Ceapro Inc.
Recognized commercial leader with over 20 years of experience across diverse healthcare industries Appointment marks strategic step in driving Company towards next phase of growth EDMONTON, Alberta,...
Ceapro Announces Results of 2022 Shareholders’ Meeting
June 07, 2022 08:05 ET
|
Ceapro Inc.
EDMONTON, Alberta, June 07, 2022 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and...
Ceapro Inc. to Present at the H.C. Wainwright Global Investment Conference
May 23, 2022 09:00 ET
|
Ceapro Inc.
EDMONTON, Alberta, May 23, 2022 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and...
Ceapro Inc. Reports Record Financial Results for First Quarter 2022 and Provides Corporate Update
May 18, 2022 09:00 ET
|
Ceapro Inc.
– Best quarterly financial results in history of the Company – Q1 2022 sales of $6,172,000 vs $4,702,000 in Q1 2021, a 31% increase – Operating profit of $2,614,000 in Q1 2022 vs $515,000 in Q1...
Ceapro Inc. Present PGX Enabling Technology Case Study at the 13th International Symposium on Supercritical Fluids
May 13, 2022 09:00 ET
|
Ceapro Inc.
EDMONTON, Alberta, May 13, 2022 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and...
Ceapro Inc. Announces Publication of Results for PGX-Processed Alginates in the Journal of CO2 Utilization
May 11, 2022 09:00 ET
|
Ceapro Inc.
– Findings from the collaborative project with the University of Alberta illustrate broad potential of the PGX Technology to generate the next generation of bioactive delivery systems – PGX...